Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGARO-BM biomarker add-on study to FIGARO-DKD
2021-003053-37Phase 2Completed
- Sponsor
- Bayer
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of finerenone in type 2 diabetes mellitus (T2DM), diabetic glomerulosclerosis and cardiac morbidity (2 arms), sponsored by Bayer. Started Aug 2021; status: completed.
02
Drugs
finerenone
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosiscardiac morbidity
Beyond the preview
Go deeper on 2021-003053-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003053-37.